A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
OverweightObesity
Interventions
DRUG

VI-0521

Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week

DRUG

Placebo

Placebo daily for 4 weeks

OTHER

Alcohol

OTHER

alcohol placebo

fruit juice

Trial Locations (1)

68502

Research Site, Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MDS Pharma Services

INDUSTRY

lead

VIVUS LLC

INDUSTRY